NCT00118313View on ClinicalTrials.gov

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

November 4, 2004

Primary Completion Date

July 28, 2006

Study Completion Date

July 28, 2006

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

multi-epitope melanoma peptide vaccine

BIOLOGICAL

sargramostim

BIOLOGICAL

tetanus toxoid helper peptide

DRUG

dimethyl sulfoxide

DRUG

imiquimod

PROCEDURE

adjuvant therapy

Trial Locations (1)

22908

University of Virginia Cancer Center, Charlottesville

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Craig L Slingluff, Jr

OTHER

NCT00118313 - Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | Biotech Hunter | Biotech Hunter